IRB Reform Is Low-Hanging Fruit For FDA-Duke Clinical Trial Initiative
This article was originally published in The Gray Sheet
One of the first jobs for a new FDA/Duke University partnership aimed at modernizing clinical trials will be reforming policies for institutional review boards so studies can get off the ground more quickly, participants say
You may also be interested in...
President Obama nominated Robert Califf for FDA commissioner, and Senate HELP Chairman Lamar Alexander said the committee "will move promptly" to consider the nomination. If confirmed, he would be expected to lead reforms of the combination products review process, among other initiatives. However, while the initial positive response from Sen. Alexander suggests the possibility of a smooth confirmation, it certainly isn't guaranteed.
Medical countermeasures expert Luciana Borio moves to chief scientist role; Hamburg offers preview of the leadership approaches of Stephen Ostroff and Robert Califf.
Robert Califf will join FDA in February as deputy commissioner for medical products and tobacco. He may be being groomed to become the next commissioner, agency watchers suggest.